Antimicrobial Agents and Chemotherapy · 2011 · 94 citations · 6 references
MedicineNephrologyPharmacotherapyRenal PathologyRenal PathophysiologyRenal PharmacotherapyAcute Kidney InjuryNephrotoxicity ManagementRenal DiseaseRenal ImpairmentRenal PharmacologyRenal ToxicityAcute Kidney Injury AssessmentAcute Kidney Injury DetectionAcute Kidney Injury DiagnosisGeriatric Drug NephrotoxicityNephrotoxicity In Critical CareSerum Creatinine AssessmentVancomycin NephrotoxicityVancomycin Toxicity
Acute kidney injury (AKI) associated with high-dose vancomycin (VAN) therapy is a clinical concern, but no uniform diagnostic criteria exist. The AKI Network (AKIN) proposed new criteria to diagnose AKI based on abrupt changes in serum creatinine or urine output. We conducted a prospective observational study to determine the incidence and severity of AKI and associated outcomes using the AKIN criteria versus traditional definitions. Eligible patients (n = 227) were elderly (median, 70 years) and received VAN therapy for 8 days (median). AKI occurred in 43 patients (19%) using AKIN criteria at an onset of 6 days. AKI incidence was similar for patients with a trough level of ≥15 (24%; 17/72) versus <15 (17%; 26/155) μg/ml. Compared to non-AKI patients, more AKI patients resided in the intensive care unit (ICU) (47% [20/43] versus 27% [50/184]; P = 0.017), had a prior AKI episode (19% [8/43] versus 7% [5/184]; P = 0.001), and received vasopressor (28% [12/43] versus 14% [25/184]; P = 0.04) and/or nephrotoxins (84% [36/43] versus 67% [123/184]; P = 0.04). Seventeen of the AKI patients met traditional criteria, of whom more patients had stage 2 and 3 AKI (76% versus 8%; P = 0.0001), dosage adjustment (41% versus 15%) and renal consultation (35% versus 12%), prolonged length of stay after AKI (11 versus 7.5 days) and died (29% versus 12%) than those diagnosed by AKIN criteria (P value not significant). Use of AKIN criteria for AKI has the potential to improve care of VAN-treated patients by facilitating early detection of AKI and warrants confirmation in large prospective trials.
6
Lesley A. Stevens, Christopher H. Schmid, Tom Greene et al. · American Journal of Kidney Diseases · 2010 · 598 citations
Meghan N. Jeffres, Warren Isakow, Joshua A. Doherty et al. · Clinical Therapeutics · 2007 · 331 citations